Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7522410 | 0.87 | L3MBTL1 (0.71) | L3MBTL1ALDH1A1HPGDMAPK1BRD4 | |
| SCHEMBL6096285 | 0.86 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1HPGDMAPK1BRD4 | |
| SCHEMBL9167530 | 0.86 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1HPGDMAPK1BRD4 | |
| SCHEMBL7680582 | 0.82 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1HPGDBRD4TSHR | |
| SCHEMBL28220176 | 0.82 | ALDH1A1 (0.58) | L3MBTL1ALDH1A1HPGDTSHRHTT | |
| SCHEMBL7484877 | 0.81 | TSHR (0.58) | L3MBTL1ALDH1A1HPGDMAPK1BRD4 | |
| SCHEMBL6097282 | 0.80 | CYP19A1 (0.51) | L3MBTL1ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL2980662 | 0.79 | HIF1A (0.44) | L3MBTL1ALDH1A1HPGDMAPK1TSHR | |
| SCHEMBL17791491 | 0.79 | TSHR (0.50) | L3MBTL1ALDH1A1HPGDMAPK1BRD4 | |
| SCHEMBL11766148 | 0.77 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPK1BRD4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115745-B2 | Benzyl urea and thiourea derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050107427-A1 | Benzyl urea and thiourea derivatives | DU DANIEL Y (US) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107427-A1 | Benzyl urea and thiourea derivatives | BRDT, TAS2R8, FSHR | L3MBTL1 4027/4885ALDH1A1 1968/4885HPGD 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.